Anavex Life Sciences Corp (AVXL)

[Gator328]

There are a ton of reasons why Anavex wasn't at AAIC.

The most likely is that there's nothing new or groundbreaking to share. They can't keep rehashing the mechanism of action over and over, and the data at this point is a continuation of what we've already seen, but there aren't enough patients or anything to make definitive conclusions. With only so many spaces available it's possible AAIC chose to have newer companies with newer projects present, which makes complete sense. If I were attending AAIC, I wouldn't be as interested in hearing about Anavex's continuation of a P2A trial either.

The less likely reason is that last time Anavex presented, within seconds there was a short attack. Given Anavex relies on a higher stock price to issue new shares to LPC, the benefit of presenting wasn't worth the risk of having the stock attacked again.

Right now we're seeing, I believe, the effects of newly issued shares flooding the market. It will subside eventually. The only question investors and traders, long and short, must ask themselves is whether Anavex 273 will go into a P3 trial. Once that happens, all bets are off as no additional data will be released until the trial is unblinded at its conclusion.